Description
Eve Technologies is proud to introduce the Human MSD® Discovery Assay® Brain Derived-pTau181 (MSDBDT181) — a highly sensitive and specific blood-based biomarker assay for Alzheimer’s disease research. This assay delivers exceptional analytical performance on the Meso Scale Discovery® (MSD®) platform, empowering scientists to explore one of the most validated and widely studied tau phosphorylation sites in neurodegenerative disease.
Why MSDBDT181?
-
Established Alzheimer’s biomarker: pTau181 is one of the most widely validated tau phosphorylation sites, strongly correlated with amyloid pathology and cognitive decline.
-
Broad matrix compatibility: Validated for serum, plasma, and CSF, enabling true blood-based utility as well as CSF studies.
-
Available on the MSD® platform, which provides the femtogram-level sensitivity and analytical precision required.
-
New and unpublished: As this assay has only just become commercially available, no publications yet exist — be among the first to publish using BD-pTau181!
Accessible Innovation
Our per-well pricing model makes advanced biomarker testing accessible and affordable — ideal for cost-effective pilots and large-scale clinical studies. You pay only for the wells you use.
Trust Experience
With 20+ years of multiplex immunoassay expertise, Eve Technologies delivers:
-
CLIA-regulated quality systems and rigorous data standards
-
Publication-grade results with rapid turnaround
-
Reliability trusted by leading academic, clinical, and industry partners
Applications
-
Alzheimer’s disease and dementia research
-
Blood-based biomarker discovery and validation
-
Clinical trial endpoint development
-
Translational studies bridging CSF and blood
Ordering Information
-
Assay Name: Human MSD® Discovery Assay® Brain Derived-pTau181 (MSDBDT181)
-
Sample Types: Serum, Plasma, or CSF
-
Platform: MSD® (electrochemiluminescence detection)